Circulating microRNA as diagnostic biomarkers for haematological cancers: a systematic review and meta-analysis
Received 24 December 2018
Accepted for publication 10 March 2019
Published 10 May 2019 Volume 2019:11 Pages 4313—4326
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Dr Alexandra R. Fernandes
Emmanuel Kwateng Drokow,1 Kai Sun,1 Hafiz Abdul Waqas Ahmed,1 Gloria Selorm Akpabla,2 Juanjuan Song,1 Mingyue Shi1
1Department of Haematology, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital Henan, Zhengzhou, People’s Republic of China; 2Department of Pathophysiology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People’s Republic of China
Purpose: Recent studies have validated microRNAs (miRNAs) as a diagnostic biomarker for haematological cancers. This study aimed to estimate the overall diagnostic accuracy of circulating miRNAs in haematological malignancies.
Materials and Methods: Multiple databases (Google Scholar, PubMed, EMBASE, Cochrane Library,) were searched until 19th, August 2017.
Results: The meta-analysis included 50 studies from 20 publications. The diagnostic accuracy was assessed by pooled specificity, sensitivity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve area (AUC) by random effect model. We used QUADAS (Quality Assessment for diagnostic accuracy studies) to evaluate the quality of the included studies. To perform the meta-analysis, we used Meta-Disk 1.4, Revman 5.3 and Stata 12.0 software. High diagnostic accuracy was demonstrated, with a sensitivity of 0.81, a specificity of 0.85, a PLR of 5.28, an NLR of 0.22, a DOR of 30.39, and an AUC of 0.91. Subgroup analyses showed better outcomes for the African population, combined miRNAs and leukaemia patients compared with other subgroups.
Conclusion: Our results indicated that circulating miRNAs especially combined miRNA can be used as a diagnostic marker in haematological cancers.
Keywords: Specificity, sensitivity, diagnostic biomarkers, miRNA, haematological cancers
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]